TIM-3 targeting on TADCs by specific mAbs was also shown to delay tumor progression in a mouse model of lymphoma, although its efficacy is not completely clear and in part controversial due to the TIM-3 expression by multiple cell types with potentially different roles [129]. Here, HAVCR2 is linked to neoplasm.